Presenter's Information
Hiroyoshi Yokoi , MD
Country | Japan |
Specialty | Interventional Cardiologist |
- Zilver PTX (Paclitaxel-Coated Stent): Transparency, Data, and Patient Safety
- DECISION Making: Endovascular vs. Surgical Approach
- Biologic and Mechanical Suppression for Restenosis: Drug-Eluting Stent
- Zilver PTX Stent for CLI - Insights from the Japan Post Market Study
- 12-Month Results from the MDT-2113 SFA Japan trial - DCB vs. Standard PTA for SFA and Proximal Popliteal Disease
- IN.PACT Admiral DCB: Results from the Japan Randomized Control Trial
- Zilver PTX Stent for CLI - Insights from the Japan Post Market Study
- Japanese Experience with Zilver PTX
- 5-Year Results of Zilver PTX Randomized Trial: DES Is Default
- Medical Treatment After Endovascular Therapy: Focus on STOP-IC
- Intervention with Pharmacologic Magic
- Statin Benefit in Atherosclerosis: Focus on Asian Population
- The Latest Technique in Endovascular CTO
- How to Maintain Long-Term Patency of SFA CTO: Pharmacologic or Technical Address